The Filing Desk

Design Therapeutics

DSGN · Nasdaq · Health Care · Financials, fiscal 2020 to 2025

DSGN · Last close · November 19, 2026
$9.32
Value Design Therapeutics yourself

Design Therapeutics reported revenue of $0 million in fiscal 2025. Free cash flow was −$55 million. The diluted share count rose 1.3%.

Design Therapeutics, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 9, 2026 · 0001193125-26-098491 Updated
Revenue
$0M
 
Net margin
—
 
Net income
−$70M
 
Free cash flow
−$55M
 
Return on equity
−30.7%
11.6 pts
Market cap
$587M
Nov 19 close
P/E
—
Loss: no P/E

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Design Therapeutics does

Design Therapeutics is a clinical-stage drug company, so it has no approved products. It is developing a new class of small-molecule drugs it calls GeneTAC molecules. They are meant to treat diseases caused by nucleotide repeat expansions, which are inherited errors in a gene where a short piece of DNA is repeated too many times.

Its lead program is for Friedreich ataxia, a disease that affects the brain and heart. Its drug candidate DT-216P2 is in a Phase 1/2 trial called RESTORE-FA. The FDA placed the program on clinical hold in June 2025 and lifted it in December 2025. The company expects an update on its effect on frataxin levels in the second half of 2026.

A second candidate, DT-168, is an eye drop for Fuchs endothelial corneal dystrophy, a disease of the cornea. It finished a Phase 1 trial in healthy volunteers in 2025. The company also has other research programs, and it relies on money it raises to fund its work.

Its biggest risks, as it describes them

  • Losses since its start, with more expected, and it may never become profitable.
  • It is early in development, and its drugs use new technology that makes results and timing hard to predict.
  • Its drug candidates may cause side effects that delay or stop their development.
  • Regulatory approval is lengthy and uncertain, and competitors may reach the market first.
From Design Therapeutics's annual report on Form 10-K, filed March 9, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Design Therapeutics lost money in fiscal 2025: a net loss of $70 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments384330282246220
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio73.0x31.1x29.6x29.3x17.1x
Quick ratio73.0x31.1x29.6x29.3x17.1x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Design Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Design Therapeutics says to expect

  • DT-216P2: registrational plan update and data timingDesign expects to provide an update on its registrational plans in the fourth quarter of 2026, with data following 12 weeks of treatment expected in the first quarter of 2027.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 4, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Design Therapeutics reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40———
Altman Z''26.8027.0615.76
Accruals ratio−2.6%−2.4%−6.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assets——Fail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Design Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Design TherapeuticsFY25——————
Aardvark TherapeuticsFY25——————Compare
ABVC BioPharmaFY25−41.9%−2,416.0%————Compare
Acadia PharmaceuticalsFY2511.9%9.8%9.8%———Compare
Aclaris TherapeuticsFY25−58.2%−975.9%−603.4%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

6 years of figures

Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue0———00
Revenue growth——————
Gross profit——————
Research and development62549574459
Operating income−8−36−68−78−62−80
Net income−8−36−63−67−50−70
Diluted EPS (US$)−0.52−0.77−1.14−1.19−0.88−1.22
Diluted shares (millions)164656565757
Cash flow
Cash from operations−9−29−51−59−43−54
Capital expenditure021000
Free cash flow−9−31−52−59−43−55
Dividends paid000000
Share buybacks000000
Acquisitions000000
Stock-based compensation0511131314
Balance sheet at fiscal year end
Cash and short-term investments36384330282246220
Debt incl. finance leases——————
Total assets36391341290252226
Total liabilities2814121014
Shareholders' equity−11382327278242212
Margins and ratios
Gross margin——————
Operating margin−3,685.8%—————
Net margin−3,663.7%—————
Free cash flow margin−3,869.5%—————
Rule of 40 (growth + FCF margin)——————
Return on capital——————
Return on equity—−19.2%−17.9%−22.1%−19.1%−30.7%
Return on assets—−16.6%−17.3%−21.2%−18.3%−29.2%
Net debt to EBITDA——————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Design Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Design Therapeutics.